Please login to the form below
urothelial carcinoma
This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
Keytruda (pembrolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in breast, urothelial, gastric and hepatocellular cancers. ... The ODAC is set to reconvene today to discuss the accelerated approval for Tecentriq as a treatment for people
Latest news
-
NICE rejects Keytruda for advanced bladder cancer in final guidance
MSD – known as Merck &Co in the US and Canada – had initially been granted authorisation for Keytruda (pembrolizumab) in advanced or metastatic urothelial carcinoma patients who had previously received platinum-based
-
FDA advisory committee to review oncology accelerated approvals
breast, urothelial, gastric and hepatocellular cancers. ... Finally, Roche announced this week that it would withdraw Tecenriq’s indication in prior-platinum treated metastatic urothelial carcinoma (bladder cancer).
-
Tecentriq misses the mark in advanced ovarian cancer
Roche’s drug is approved in a range of cancer types, including urothelial carcinoma, triple-negative cancer and hepatocellular carcinoma.
-
Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer
At the tail-end of last year, Seattle and Astellas scored US approval for Padcev (enfortumab vedotin) for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form ... The initial results from the phase 1b/2 EV-103
-
Keytruda claims first place in bladder cancer race
covers patients with early-stage high grade cancer cells – carcinoma-in-situ (CIS) – with or without papillary tumours. ... Keytruda has already been approved for first- and second-line treatment of urothelial carcinoma, another form of bladder
NICE rejects Keytruda for advanced bladder cancer in final guidance
FDA advisory committee to review oncology accelerated approvals
Tecentriq misses the mark in advanced ovarian cancer
Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer
Keytruda claims first place in bladder cancer race
More from news
Approximately 3 fully matching, plus 36 partially matching documents found.
Latest Intelligence
-
Unlocking the potential of precision medicine in oncology
those living with urothelial carcinoma (UC), the most common type of bladder cancer.
-
Europe vs the US: New drug product approvals
Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).
Unlocking the potential of precision medicine in oncology
Europe vs the US: New drug product approvals
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
